Breaking News

ICON Appoints CMO

July 2, 2013

Buckley brings 30 years of experience

Professor Brendan Buckley has been appointed chief medical officer at ICON plc. Professor Buckley will be ICON’s lead medical expert, representing the company’s position on key scientific, ethical and medical governance matters, as well as provide guidance and oversight to the medical and scientific groups.
 
Professor Buckley is an endocrinologist with more than 30 years of experience. He joined ICON through the acquisition of Firecrest Clinical in 2011, where he was one of the founders of the company and senior vice president of Medical Affairs. He has extensive experience in clinical trials and chairs several independent Data and Safety Monitoring Boards. Mr. Buckley is Clinical Professor of Medicine and Pharmacology at the School of Medicine, University College Cork (UCC), Ireland. 
 
Ciaran Murray, chief executive officer ICON plc, said, “I would like to congratulate Brendan on his new role and welcome him to ICON’s executive leadership team. Brendan’s wealth of experience both as an advisor to European regulatory agencies and a physician with over 30 years of clinical trial experience, will help us advance our clients' products through their development pipelines and ensure ICON studies continue to be performed to the highest scientific and ethical standards.”
  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research